Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.727
-0.533 (-12.50%)
Mar 16, 2026, 2:49 PM EDT - Market open
Evaxion Employees
Evaxion had 46 employees as of December 31, 2024. The number of employees decreased by 3 or -6.12% compared to the previous year.
Employees
46
Change (1Y)
-3
Growth (1Y)
-6.12%
Revenue / Employee
$163,652
Profits / Employee
-$167,543
Market Cap
155.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 46 | -3 | -6.12% |
| Dec 31, 2023 | 49 | -14 | -22.22% |
| Dec 31, 2022 | 63 | 2 | 3.28% |
| Dec 31, 2021 | 61 | 26 | 74.29% |
| Dec 31, 2020 | 35 | -1 | -2.78% |
| Sep 30, 2020 | 32 | -4 | -11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Xilio Therapeutics | 64 |
| Werewolf Therapeutics | 39 |
| Jasper Therapeutics | 27 |
| Actinium Pharmaceuticals | 25 |
| PDS Biotechnology | 24 |
| INmune Bio | 22 |
EVAX News
- 9 days ago - Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Evaxion announces business update and full year 2025 financial results - GlobeNewsWire
- 11 days ago - Evaxion plans to file 2025 annual report later today - GlobeNewsWire
- 14 days ago - Evaxion to announce business update and full year 2025 financial results on March 5, 2026 - GlobeNewsWire
- 2 months ago - Evaxion expands AI-Immunology™ platform into autoimmune diseases - GlobeNewsWire
- 2 months ago - Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week - GlobeNewsWire
- 3 months ago - Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Benzinga
- 3 months ago - Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 - GlobeNewsWire